Cocrystal Pharma, Inc. recently released its financial report for fiscal year 2025 and provided an update on the latest progress in its antiviral drug development projects.

As a biopharmaceutical company focused on developing innovative antiviral therapies, Cocrystal Pharma continues to invest in research and development with the goal of addressing the severe challenges of viral infections worldwide. Financial data shows that the company maintained a stable financial position in the 2025 fiscal year, providing strong support for subsequent clinical research and pipeline advancement. Meanwhile, the research and development team has achieved phased results in multiple antiviral projects targeting influenza, coronavirus, and norovirus, further validating the potential of its proprietary technology platform. The company will continue to optimize the efficacy and safety of candidate drugs and accelerate progress towards the clinical stage. Looking ahead, Cocrystal Pharma plans to continuously expand its antiviral product portfolio through a dual strategy of strategic partnerships and internal R&D, providing innovative solutions for unmet medical needs.